2768-LB: Evaluation of a Nutrition Program Using a Diabetes-Specific Formula with Beta-hydroxy-beta-methylbutyrate (HMB) on Metabolic and Muscle Health in Patients with Type 2 Diabetes With or at Risk of Malnutrition

Introduction and Objective: In adults with type 2 diabetes (T2DM) malnutrition (MN) and sarcopenia are highly prevalent and are associated with adverse clinical outcomes. This study evaluated the impact of a nutrition support program including a high-protein, diabetes-specific nutrition formula with β-hydroxy β-methylbutyrate (HP-DSNF+HMB)) on nutritional, glycaemic, functional and body composition outcomes in outpatients with T2DM with or at risk of MN. Methods: A prospective real-world evidence study was conducted in 16 Spanish outpatient clinics. Adults with T2DM and Malnutrition Universal Screening Tool (MUST) score ≥2 received dietary and physical exercise guidance with 2 daily servings of HP-DSNF+HMB for 90 days. Primary outcome was change in MN risk (MUST). Results: Patients had a mean age (±SE) of 69 (±0.7) years (n=193), 73% were male, all were at high risk of MN and 53.4% had severe MN using Global Leadership Initiative on Malnutrition criteria. Among 166 participants with paired MUST data, 64.5% improved their MN risk category (p0.0001), rising to 66.3% in those with ≥70% supplement adherence. Significant improvements were also observed in nutritional status, while body weight was stable. Fasting blood glucose (-9.9 (±4.2) mg/dL, p=0.020) improved with no significant changes in HbA1c. Chair stand test performance (+1.3 (±0.3) rises/30s, p0.0001) improved, alongside increases in fat-free mass (+1.1 (±0.4) kg, p=0.011), phase angle (+0.5° (±0.05), p0.0001) and body cell mass (+2 (±0.3) kg, p0.0001), and improved sarcopenia risk, reduced diabetes distress and enhanced quality-of-life. Vitamin D levels significantly increased. Conclusion: A multi-modal nutritional program using a HP-DSNF+HMB was associated with clinically meaningful improvements in nutritional, metabolic and muscle health-related outcomes with good acceptability and adherence, supporting feasibility for real-world clinical practice. Disclosure J.M. Garcia Almeida: None. J. Guardia-Baena: Advisory Panel; Ended; Abbott. Speaker's Bureau; Ended; Nestlé. Advisory Panel; Ended; Nutricia, Fresenius Medical Care, Pfizer Inc. S. Palma: None. M. Camprubi Robles: Employee; Current; Abbott. G. Guzman: Employee; Current; Abbott. G.E. Baggs: Employee; Current; Abbott. Stock/Shareholder; Current; Abbott, AbbVie Inc. P.P. Suryawanshi: None. J. Barranco Ochoa: Stock/Shareholder; Current; Novo Nordisk A/S. Advisory Panel; Current; Nutrisens. Stock/Shareholder; Ended; Eli Lilly and Company. A. Moyano: None. J.F. Merino-Torres: None. M. Civera: Speaker's Bureau; Ended; Eli Lilly and Company, Novo Nordisk, Fresenius Medical Care. P. Garcia-Luna: None. G.O. Olveira: Research Support; Current; Abbott, Nestlé Health Science. Research Support; Ended; Fresenius Medical Care. Research Support; Current; Nutricia. J.I. Botella-Carretero: Research Support; Ended; Abbott. Speaker's Bureau; Current; Fresenius Medical Care, Lilly. Speaker's Bureau; Ended; Baxter. Research Support; Current; Nutrisens. M. Rebollo: Research Support; Ended; Abbott. Advisory Panel; Ended; Fresenius Medical Care. Research Support; Ended; Nestlé. Advisory Panel; Ended; Nestlé. F. Vílchez-López: Research Support; Current; Nestlé, Abbott, Fresenius Medical Care. Speaker's Bureau; Ended; Nutricia. Research Support; Current; Persan. M. Maíz Jiménez: None. Y. García Delgado: None. L.A. Calles Romero: None. M. Amaya: None. P. Espinosa de los Monteros Sicilia: None.